AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

The utility of AsCas12a can be limited to poor editing efficiency. Here the authors identify a variant, “AsCas12a Ultra”, that has high on-target specificity demonstrated through editing of clinically relevant T cell genes.

Bibliographic Details
Main Authors: Liyang Zhang, John A. Zuris, Ramya Viswanathan, Jasmine N. Edelstein, Rolf Turk, Bernice Thommandru, H. Tomas Rube, Steve E. Glenn, Michael A. Collingwood, Nicole M. Bode, Sarah F. Beaudoin, Swarali Lele, Sean N. Scott, Kevin M. Wasko, Steven Sexton, Christopher M. Borges, Mollie S. Schubert, Gavin L. Kurgan, Matthew S. McNeill, Cecilia A. Fernandez, Vic E. Myer, Richard A. Morgan, Mark A. Behlke, Christopher A. Vakulskas
Format: Article
Language:English
Published: Nature Portfolio 2021-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-24017-8

Internet

https://doi.org/10.1038/s41467-021-24017-8

Similar Items